 |
Clinical Risk |
 |
Home Site Map This Site Is For Sale |
Clinical Risk
Clinical Risk Self-Assessment for GP practices -- What's involved?May 04, 2012 Julie Wilson, Clinical Risk Programme Manager, explains what's involved in an MPS Clinical Risk Self-Assessment (CRSA). CRSA's are available to GP practices in the UK and Ireland. For further information, visit: www.mps.org.uk/crsa. 
Epidemiology, Clinical Features, High-Risk Factors, and Outcome of Acute Large Bowel IschemiaOct 14, 2010 Dr. George F. Longstreth discusses his manuscript "Epidemiology, Clinical Features, High-Risk Factors, and Outcome of Acute Large Bowel Ischemia." To view the print version of this abstract go to: tiny.cc 
Kidney Transplant: Risks and OutcomesApr 25, 2012 The UCSF Transplant Update Series brings the latest clinical information for physicians, nurses, allied health professionals and others who care for organ failure patients. This program provides an update in transplant outcomes at UCSF by Stephen Tomlanovich, MD, a survey of current clinical trials in kidney transplant by Flavio Vincenti, MD, and vital information on evaluating risks for potential kidney donors by Andrew Posselt, MD Series: UCSF Transplant Update [9/2007] [Health and Medicine] [Professional Medical Education] [Show ID: 12987] 
Biomarkers for Type 2 Diabetes PreventionApr 24, 2012 Simin Liu is currently Professor of Epidemiology and Medicine, founding director of the Program on Genomics and Nutrition at the UCLA School of Public Health and co-founder of the Burroughs Wellcome Fund Interschool Training Program in Metabolic Diseases. Lius current research is at the interface of nutrition and genetics/genomics and focuses on their interplay in affecting major chronic diseases in human populations. He discusses translating epidemiologic observations to clinical risk stratification and intervention in type 2 diabetes. Series: Translational Research for Metabolic Disease Prevention [2/2010] [Health and Medicine] [Professional Medical Education] [Show ID: 17967] 
Dr. Simin Liu, Metabolic Disease PreventionApr 14, 2012 Faculty speaker: Dr. Simin Liu, Biomarkers for type 2 diabetes prevention: translating epidemiologic observations to clinical risk stratification and intervention from the UCLA Symposium, Translational Research for Metabolic Disease Prevention: From Molecules to Populations. Held by the newly formed UCLA Center for Metabolic Disease Prevention, this symposium explores the interdisciplinary study of metabolic diseases and focuses on the need for integration from molecules to populations to curb this epidemic. (www.mdtp.mednet.ucla.edu 
Massive Whooping Cough Vaccine Failure: Are The Vaccinated at Higher Risk?May 20, 2012 This is my response to some recent articles showing the failure of the DTP vaccine in older children. The vaccine has been shown to wear off after some time, but are vaccinated children actually at higher risk of developing clinical whooping cough (pertussis) than the unvaccinated? As you will see, the vaccine protects only against clinical disease, not against subclinical (mild) disease or infection, and the vaccinated can serve as reservoirs to spread disease. The result is that over the years, whooping cough deaths in infants, who are most at risk of dying from this infection, have steadily risen over the past decades. This demonstrates that vaccinating older children and adults will never serve to protect the most vulnerable and will actually put them at greater risk, as the vaccinated continue to spread disease to them. While the vaccine does offer some protection, this has to be weighed against the risk of SIDS and other adverse effects caused by the vaccine, such as encephalitis which can lead to brain damage, autoimmune disease from the injection of foreign animal proteins, and toxicity from and overload of aluminum adjuvant . www.naturalnews.com www.reuters.com Vaccine failure study in Israel: www.ncbi.nlm.nih.gov DTP shot and pertussis info on my website: thetruthergirls.com adverse cardiorespiratory effects in babies: www.ncbi.nlm.nih.gov 
Mayo Clinic Study on Radiation Risks of AngioplastyAug 12, 2011 Body size, gender and the complexity of heart disease significantly influence how much cumulative radiation skin dose that patients receive during percutaneous coronary intervention (PCI) therapy, also known as angioplasty, according to a new Mayo Clinic study. The study was undertaken as a quality control initiative to reduce the potential radiation risks of cancer to patients and PCI operators. Presented today at the annual meeting of the American College of Cardiology, the review of 14 months worth of radiation data from 1827 adult patients is an important early step in understanding ways to improve PCI safety and quality while optimizing therapeutic benefits. The Mayo Clinic study identified 20 clinical traits and circumstances that help predict whether a patient likely received higher or lower doses of radiation. Significance Identifying optimal means of using radiation in PCI is important because a chief advantage of PCI is its minimally-invasive nature in successfully opening vessels and placing stents, which makes it an increasingly popular option for treating select cases of heart disease. PCIs minimally-invasive advantages include reducing patient trauma, speeding recovery and lowering costs, compared to traditional heart surgeries. However, PCI owes its precision, safety and effectiveness to the X-ray fluoroscopy imaging used. X-ray fluoroscopy produces many images to make a movie that allows physicians to visualize the intricate vessel anatomy being treated ... 
CMR OverviewMar 22, 2012 The current definition of the metabolic syndrome encompasses a cluster of metabolic abnormalities linked to insulin resistance, which is often associated with a high-risk form of overweight/obesity: excess abdominal obesity. Because these abnormalities increase the risk of cardiovascular disease (CVD) and type 2 diabetes, numerous consensus groups have attempted to provide guidelines to identify patients in clinical practice with these atherogenic/diabetogenic metabolic abnormalities. Although the number of publications on the metabolic syndrome is soaring, the concept of a cluster of abnormalities including obesity, diabetes, dyslipidemia, and hypertension is not new and several physicians/investigators contributed to the development of this concept through astute clinical observations or epidemiological/metabolic studies. However, a clinical diagnosis of the metabolic syndrome is not sufficient to assess the risk of CVD. In order to properly evaluate and manage global CVD risk in clinical practice, it is important to take into account the risk associated with traditional risk factors as well as the potential additional contribution of abdominal obesity/insulin resistance and related complications. This global risk is referred to as global cardiometabolic risk. 
H1N1 Vaccine Miscarriage RiskMay 19, 2012 It is stated plainly in the Arepanrix adjuvanted H1N1 vaccine package that the product was associated with miscarriage, birth defects and developmental delays in rats.Nonetheless, our government continues to recommend that pregnant women take the adjuvanted vaccine if flu rates are increasing and they are unable to get the unadjuvanted version at that time. How can our public health officials consider this an acceptable risk/benefit ratio?About 1 in 450 pregnant women who catch influenza will go on to develop complications. According to data from Australian epidemiological surveillance, one in 3800 pregnant women are hospitalized for flu-related complications, but these women had other risk factors such as obesity. The risk of pregnant women dying from flu was found to be about 1/300000. articles.mercola.com So far, there has only been one "H1N1-related" death in a pregnant woman in Canada since the virus first appeared in April, and this woman actually died of blood loss following an emergency C-section done because she was suffering respiratory distress. In other words, the flu was only very loosely connected to a single death. Meanwhile, the vaccine has to date never been tested in pregnant women and is known to have adverse outcomes in the offspring of treated rats. Clinical trials on pregnat women were SUSPENDED because the women developed fever, which is known to affect fetal development. Whether the public health officials are totally incompetent or are being ... 
Recognising Risk and Improving Patient Safety - Mildred's StoryApr 20, 2012 Patient Safety - Mildred's Story Mildred's Story was produced to form part of a 'Recognising Risk and Improving Patient Safety' course. The course takes a novel approach to educating healthcare professionals about the importance of non-clinical skills, behaviour and attitudes in assuring patient safety. It draws upon the experiences of patients within healthcare settings, and knowledge gained from other high-risk industries, to develop a strategy enabling healthcare workers to critically appraise and intervene in the development of patient risk. Mildred's Story has been reconstructed from the actual experiences of a number of patients. Part One (Mildred's Flat) Introductory/Exemplary Care Part Two (A & E Department) Situational Awareness Part Three (Care of the Elderly Ward) Communication Part Four (Outside Theatre) Leadership Part Five (Recovery Room) Empowerment Part Six (Orthopaedic Ward) Empowerment The film was produced with financial assistance from the National Patient Safety Agency. It was directed and filmed by University of Leicester ITS-Multimedia Services and written by Paul Allsop, Steve Overton, Nicole Stewart and Paul Stewart. 
Radiation & Your Food, Irradiated Food Risk, Wake Up AmericaMay 20, 2012 Radiation & Your Food, Irradiated Food Risk, Wake Up America Radhia and Peter discuss the effects of treating food with radiation including what it does to antioxidants, enzymes and nutrients such as vitamins and minerals. Is it safe to eat irradiated food? Be My Friend www.myspace.com Visit Radhia's Website at www.advancedhealthinstitute.com www.aimmd.com Visit Peter McCarthy's website www.lifeenergyholisticcenter.com Visit Texas Health Freedom Coalition www.texashealthfreedom.com Radhia Gleis is certified in Clinical Nutrition, CCN She is also a Certified BioNutritional Analyst. Music by John Richter http This video was produced by Psychetruth www.myspace.com www.youtube.com psychetruth.blogspot.com Psychetruth is empowered by TubeMogul www.tubemogul.com © Copyright 2008 AHI Productions. All Rights Reserved. 
Clinical Institute Withdrawal Assessment (CIWA)Feb 27, 2012 The CIWA (Clinical Institute Withdrawal Assessment) is a common measure used in North American hospitals to assess and treat Alcohol withdrawal syndrome and for Alcohol detoxification. This clinical tool assesses 10 common withdrawal signs. A score of more than 15 points is associated with increased risk of alcohol withdrawal effects such as confusion or seizures. Slide show: 00:00 - 09:30 min. Scenarios: 09:30 - 27:47 min. 
Study of Microbicide Gel Shows Reduced Risk of HIV & Herpes Infections in WomenJan 26, 2012 FHI contributed to a clinical trial in South Africa of a vaginal gel that has been shown to be 39% effective in reducing women's risk of HIV infection and 51% effective in preventing new herpes infections. 
Good Clinical Practice: Practical Application and ImplementationAug 15, 2011 This seminar provides an overview of the structural elements of Good Clinical Practice (GCP). Participants will learn practical application of GCP regulations and guidelines for critical components of the clinical research process. Specific attention will be given to how quality systems, or a lack thereof, impact overall data quality and regulatory risk. This seminar is designed for professionals with at least two years of experience in the clinical research industry. 
Risk of Suicidality in Children Treated w Strattera (Dec 05)May 02, 2012 FDA recently alerted health care providers that treatment of children and adolescents with Strattera increases the risk of suicidal thinking. Strattera (atomoxetine) is approved to treat ADHD in patients 6 years and older. The increased risk of suicidal thinking was identified in a combined analysis of 12 placebo-controlled trials lasting six to eighteen weeks. This analysis showed that 0.4% of children treated with Strattera reported suicidal thinking compared to no reports in children treated with placebo. A similar analysis in adults treated with Straterra for either ADHD or major depressive disorder found no increased risk of suicidality with use of the drug. A new boxed warning will point out that children who are started on Strattera therapy should be observed closely for suicidal thinking or behaviors, clinical worsening, or unusual changes in behavior. This is especially important during the initial months of therapy or when the dose is changed. Families should contact their child's doctor if they observe any of these signs. Eli Lilly, the drug's manufacturer, will also be developing a Patient Medication Guide to provide this information directly to patients and their caregivers. Additional Information: FDA MedWatch Safety Alert - Strattera (atamoxetine). www.fda.gov 
|
|
||||||||
